Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

This study found serum protein test status to be predictive of differential survival benefit for erlotinib v chemotherapy in the 2nd-line treatment of NSCLC. Those with a proteomic test classification of poor had worse survival on erlotinib (HR 1.72; 95% CI 1.08-2.74; p=0.022).